Why the study?
AF commonly coexists with advanced age and multiple comorbidities that increase risk for serious adverse effects, prompting an evaluation of the effectiveness and safety of NOACs in high-bleeding-risk patients in real-world practice.
Does NOAC therapy have acceptable safety and effectiveness in high-bleeding-risk patients with non-valvular atrial fibrillation?
Does NOAC therapy have acceptable safety and effectiveness in high-bleeding-risk patients with non-valvular atrial fibrillation?
In a real-world cohort of high-bleeding-risk patients with non-valvular atrial fibrillation, NOACs demonstrated acceptable rates of major bleeding and stroke.
No takes yet. Share an insight, caveat, or question.
Supports cautious NOAC use in high-bleeding-risk elderly AF; leaves open randomized comparison versus VKA.
Cunha et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: